Artículos por temáticas

Defining the spectrum of spasticity-associated involuntary movements.

Abboud H, Macaron G, Yu XX, Knusel K, Fernandez HH, Bethoux F.

Parkinsonism Relat Disord. 2019 May 12. pii: S1353-8020(19)30228-7. doi: 10.1016/j.parkreldis.2019.05.007. [Epub ahead of print]

Residual Descending Motor Pathways Influence Spasticity after Spinal Cord Injury.

Sangari S, Lundell H, Kirshblum S, Perez MA.

Ann Neurol. 2019 May 18. doi: 10.1002/ana.25505. [Epub ahead of print]

When does spasticity in the upper limb develop after a first stroke? A nationwide observational study on 861 stroke patients.

Nam KE, Lim SH, Kim JS, Hong BY, Jung HY, Lee JK, Yoo SD, Pyun SB, Lee KM, Lee KJ, Kim H, Han EY, Lee KW.

J Clin Neurosci. 2019 May 11. pii: S0967-5868(18)31764-8. doi: 10.1016/j.jocn.2019.04.034. [Epub ahead of print]

Stumbling, struggling, and shame due to spasticity: a qualitative study of adult persons with hereditary spastic paraplegia

Kerstens HCJW, Satink T, Nijkrake MJ, De Swart BJM, Van Lith BJH, Geurts ACH, Nijhuis-van der Sanden MWG.

Disabil Rehabil. 2020 Dec;42(26):3744-3751. doi: 10.1080/09638288.2019.1610084. Epub 2019 May 13.

Efficacy of botulinum toxin in modifying spasticity to improve walking and quality of life in post-stroke lower limb spasticity - a randomized double-blind placebo controlled study.

Datta Gupta A, Visvanathan R, Cameron I, Koblar SA, Howell S, Wilson D.

BMC Neurol. 2019 May 11;19(1):96. doi: 10.1186/s12883-019-1325-3.

Duration of Treatment Effect of Extracorporeal Shock Wave on Spasticity and Subgroup-Analysis According to Number of Shocks and Application Site: A Meta-Analysis.

Oh JH, Park HD, Han SH, Shim GY, Choi KY.

Ann Rehabil Med. 2019 Apr;43(2):163-177. doi: 10.5535/arm.2019.43.2.163. Epub 2019 Apr 30.

Botulinum toxin treatment of spasticity targeted to muscle endplates: an international, randomised, evaluator-blinded study comparing two different botulinum toxin injection strategies for the treatment of upper limb spasticity.

Rekand T, Biering-Sörensen B, He J, Vilholm OJ, Christensen PB, Ulfarsson T, Belusa R, Ström T, Myrenfors P, Maisonobe P, Dalager T.

BMJ Open. 2019 May 5;9(5):e024340. doi: 10.1136/bmjopen-2018-024340.

Successful Treatment of Central Pain and Spasticity in Patient With Multiple Sclerosis With Dorsal Column, Paresthesia-Free Spinal Cord Stimulator: A Case Report.

Lam CM, Monroe BR.

A A Pract. 2019 May 1;12(9):308-312. doi: 10.1213/XAA.0000000000000918.

Optimal Muscle Selection for OnabotulinumtoxinA Injections in Poststroke Lower-Limb Spasticity: A Randomized Trial.

Esquenazi A, Wein TH, Ward AB, Geis C, Liu C, Dimitrova R.

Am J Phys Med Rehabil. 2019 May;98(5):360-368. doi: 10.1097/PHM.0000000000001101.

Treatment of psychiatric disturbances in hypokinetic movement disorders.

Berardelli I, Belvisi D, Pasquini M, Fabbrini A, Petrini F, Fabbrini G.

Expert Rev Neurother. 2019 Jun 26. doi: 10.1080/14737175.2019.1636648. [Epub ahead of print]

Neuropathology and pathogenesis of extrapyramidal movement disorders: a critical update. II. Hyperkinetic disorders.

Jellinger KA.

J Neural Transm (Vienna). 2019 Jun 24. doi: 10.1007/s00702-019-02030-y. [Epub ahead of print] Review.

Botulinum neurotoxin treatment in jerky and tremulous functional movement disorders: a double-blind, randomised placebo-controlled trial with an open-label extension.

Dreissen YEM, Dijk JM, Gelauff JM, Zoons E, van Poppelen D, Contarino MF, Zutt R, Post B, Munts AG, Speelman JD, Cath DC, de Haan RJ, Koelman JH, Tijssen MAJ.

J Neurol Neurosurg Psychiatry. 2019 Jun 20. pii: jnnp-2018-320071. doi: 10.1136/jnnp-2018-320071. [Epub ahead of print]

Update on movement disorders.

Svenningsson P, Frucht SJ.

Curr Opin Neurol. 2019 Jun 18. doi: 10.1097/WCO.0000000000000709. [Epub ahead of print] No abstract available.

Neuropathology and pathogenesis of extrapyramidal movement disorders: a critical update-I. Hypokinetic-rigid movement disorders.

Jellinger KA.

J Neural Transm (Vienna). 2019 Jun 18. doi: 10.1007/s00702-019-02028-6. [Epub ahead of print] Review.

Roles of the M(4) acetylcholine receptor in the basal ganglia and the treatment of movement disorders.

Moehle MS, Conn PJ.

Mov Disord. 2019 Jun 18. doi: 10.1002/mds.27740. [Epub ahead of print]